Synlogic gets grant for genetically engineered bacteria for attenuating metabolic diseases
Pharmaceutical Technology
APRIL 22, 2024
Discover how Synlogic Inc's patented genetically engineered bacteria produce short-chain fatty acids to combat metabolic diseases. Learn more about this innovative treatment approach.
Let's personalize your content